Sentrx™ Animal Care, Inc. Announces Manufacturing Facility Expansion to Accommodate Accelerated Growth
1.7.2021 17:03:00 EEST | Business Wire | Press release
On May 20th, 2021 Sentrx Animal Care held a ribbon cutting ceremony to celebrate the completion and opening of its brand new 22,000 square foot manufacturing facility in Salt Lake City, Utah. The expansion into this larger new facility represents a major milestone for the Salt Lake City based company. The design of the new space includes 1,689 square feet of ISO 7 clean room and 1,420 square feet of wet lab, accommodating the manufacturing capacity and capabilities required to support Sentrx’s accelerating growth in the United States, and in new markets abroad, as well as expanding R&D initiatives that build upon Sentrx’s patented BioHAnce platform technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210701005040/en/
Sentrx ribbon-cutting ceremony for new facility in Salt Lake City, Utah (Photo: Business Wire)
Working with Engage Contracting, Inc. as the general contractor on the project, Sentrx broke ground in November 2020. By the end of April 2021, manufacturing was online and fully validated in the new space. Sentrx also completed ISO audits in April and maintains ISO 13485 certification in this new facility.
“The completion of this project marks an exciting milestone for Sentrx,” said Brian Segebrecht, Chief Executive Officer. “Sentrx runs a vertically integrated manufacturing operation, procuring only raw materials and components from third parties. This allows for complete control over quality and the highly proprietary processes we have developed for manufacturing our three in-market formulations at large commercial scale. Our expansion to this new facility ensures our ability to remain a vertically integrated manufacturing operation with the capacity required to support the accelerating growth of our in-market products, as well as the robust pipeline of future innovation we have planned for the BioHAnce platform.”
Sentrx was founded on exclusive, worldwide rights to BioHAnce Technology, a patented and proprietary technology that uses advanced bioengineering to create a molecular matrix of crosslinked hyaluronic acid (HA) that can be specifically modified for each formulation and particular tissue environment, including ocular and skin surfaces. It produces a cellular scaffolding with unique physical and chemical properties that enhances hydration, accelerates the body’s own healing processes, and extends duration in tissue. Sentrx currently sells three product formulations containing the BioHAnce Technology. In the US these products are marketed under the brand names Ocunovis™, Oculenis™ and Episanis™.
Related Information
Sentrx™ Animal Care, Inc. website: www.sentrxanimalcare.com
Online press releases: www.sentrxanimalcare.com/news
Sign up for the Sentrx veterinarian newsletter here
Product information:
Ocunovis™ BioHAnce™ Gel Eye Drops
Oculenis™ BioHAnce™ Ocular Repair Gel
Episanis™ BioHAnce™ Skin and Wound Gel
About Sentrx™ Animal Care, Inc.
Sentrx is a Salt Lake City-based animal health company that develops and manufactures veterinary wound care and ophthalmic products for companion animals. Sentrx transforms complex biotechnologies into easy-to-use care solutions that promote the long-term well-being of animals.
Sentrx was founded on technology from the University of Utah and collaborates with a variety of veterinary academic institutions and practicing veterinarians. The company’s unique combination of medicinal chemistry, bioengineering, and product manufacturing capabilities allow it to deliver cutting-edge animal care solutions. To learn more, visit our website at sentrxanimalcare.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210701005040/en/
Contact information
Mason Williams, Chief Commercial Officer
Sentrx™ Animal Care, Inc.
(801) 583-2050
mwilliams@sentrxanimalcare.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Paris Outpaces London as Europe’s Top AI City, According to The Observer’s AI Cities Index20.10.2026 14:11:00 EEST | Press release
Paris has claimed Europe’s AI crown, ranking higher than London as the continent’s leading hub of AI excellence. Yet Europe is struggling to compete with cities across the US and Asia, whose AI hubs lead the global rankings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020799504/en/ The Observer AI Cities Index Top Ten Cities 2026 This is according to The Observer’s inaugural AI Cities Index: a first-of-its-kind report identifying which cities are leading the global AI race when it comes to originating, building, financing and integratingartificial intelligence (AI). The new ranking has scored 57 cities across 36 countries based on levels of AI investment (assessing public, private and procedural investments in AI), innovation (capturing breakthroughs in technology that are indicative of greater capacity for AI in the future) and implementation (the availability of the infrastructure, institutions and systems needed to
New Research from One Biosciences Shows Single-Cell Profiling Can Identify Which Ovarian Cancer Tumors are Predisposed to Chemotherapy Resistance20.10.2026 14:02:00 EEST | Press release
One Biosciences today announced data showing some ovarian cancer tumor cells are predisposed to resist chemotherapy and single-cell profiling at diagnosis can identify tumor profiles that indicate which patients are likely to experience treatment failure, ultimately enabling more personalized treatment strategies. Researchers from One Biosciences, French National Centre for Scientific Research (CNRS), Institut Curie, and Sorbonne Université found that the cellular changes linked to the development of resistance to cytotoxic chemotherapy cannot be explained by DNA mutations alone: the functional and epigenetic state of tumor cells play a key role and initial tumor composition predicts overall survival. The study focused on patients with high grade serous ovarian cancer (HGSOC), the most common and aggressive type of ovarian cancer. The disease has few symptoms, is often identified late and remains difficult to treat, with a five-year survival rate below 40 percent. “Ovarian cancer tumor
IDWS 2026 Brings the World Together to Accelerate the Deployment of Water Solutions20.10.2026 13:38:00 EEST | Press release
Jeddah is preparing to host the fifth edition of the Innovation Driven Water Sustainability Conference (IDWS 2026) from 14 to 16 December 2026. The conference aims to accelerate the transition of water solutions from research and development to real-world deployment, while connecting innovators with investors and end users to strengthen water security, improve service efficiency, and enhance the sustainability of water resources worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020192877/en/ Main session from IDWS 2025 (Photo: AETOSWire) The conference will bring together experts, researchers, innovators, investors, and representatives of water-sector organisations from more than 140 countries. It will feature over 250 speakers and is expected to attract more than 10,000 participants, alongside an international exhibition showcasing more than 150 global brands. Eng. Tariq Al-Ghafari, Deputy president for innovatio
European Wealth Firms Build Private Markets Capability Faster Than They Communicate It, Peregrine Report Finds20.10.2026 11:15:00 EEST | Press release
Europe's leading wealth managers have built genuine private markets capability but most have yet to explain it to the clients they built it for, according to The Wealth 30, a new report from Peregrine Communications. The study analyses how 30 leading UK and European wealth managers and private banks position private markets. It concludes that communication, not product, is now the biggest barrier to differentiation in the wealth channel. Capability outpaces explanation 73% of the Wealth 30 engage in private markets yet only 40% operate a dedicated landing page explaining what private markets are, why they matter and how clients can access them. Just 23% combine explainers, a destination and repeatable house-view content. Swiss private banks set the benchmark, supported by house views, outlooks and heritage narratives. Pictet, UBP, Lombard Odier and Julius Baer all back their positioning with repeatable insight content, and Coutts is the clearest UK example. UK firms more often communic
Infobip and Yamaha Power Conversational Customer Engagement in Indonesia’s Automotive Sector20.10.2026 11:00:00 EEST | Press release
Global AI-first cloud communications platform Infobip strengthens its collaboration with Yamaha Indonesia Motor Manufacturing (YIMM) to transform customer engagement through WhatsApp-powered conversational experiences designed to drive stronger personalization and faster customer interactions. As Indonesia’s consumers increasingly adopt digital-first purchasing behaviors, Yamaha Indonesia is evolving how it connects with customers across the buying journey. Today’s motorcycle buyers often research products through Yamaha’s social media, websites, and video reviews on YouTube before visiting dealerships, raising expectations for brands to deliver fast, seamless, and highly personalized communication. For more than two years, Infobip has supported Yamaha Indonesia in building connected customer engagement strategies that integrate WhatsApp across the company’s wider digital ecosystem, including its websites, social media platforms, and customer touchpoints. The collaboration reflects the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom